about
Genetics of psoriasis and pharmacogenetics of biological drugsThe Patient's Guide to Psoriasis Treatment. Part 3: Biologic InjectablesBrodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsIxekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsThe role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritisEndothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: Characterization and role in human autoimmune diseasesBiologics in dermatology: an integrated reviewImmune Components of Liver Damage Associated with Connective Tissue DiseasesInterleukin-1 loop model for pathogenesis of Langerhans cell histiocytosisAnti-IL-17 phase II data for psoriasis: A review.Bone marrow-derived mesenchymal stem cells affect immunologic profiling of interleukin-17-secreting cells in a chemical burn mouse model.S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.New insights of T cells in the pathogenesis of psoriasisIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perioThe danger model approach to the pathogenesis of the rheumatic diseases.Correlation of IL-17 Level in Synovia and Severity of Knee Osteoarthritis.Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations.Mechanisms of action of topical corticosteroids in psoriasisNorepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells.Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis.Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus ClearanceMechanistic rationales for targeting interleukin-17A in spondyloarthritis.New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Keratin 17: a critical player in the pathogenesis of psoriasis.Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.Pharmacogenetics of topical and systemic treatment of psoriasis.The role of T helper (TH)17 cells as a double-edged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation.Diagnosing and treating psoriatic arthritis: an update.Autoimmunity in 2013.CD4 T-cell memory generation and maintenanceInterleukin-17 in human inflammatory diseases.Focal bone involvement in inflammatory arthritis: the role of IL17.Multicentric reticulohistiocytosis: a critical review.Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.The genomic landscape of human immune-mediated diseases.Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.New therapies for psoriasis and psoriatic arthritis.New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis.
P2860
Q21284816-11EAE4A6-9A1A-4A21-9F29-7BF69A9EF3B9Q26740450-1C9CC737-B470-4919-87F7-73FBADB07D29Q26746100-683C2385-9446-4C95-B9BB-6AF4A2289573Q26766567-7A8CFEA2-3112-4CAB-BECE-4AD522D3763DQ26821943-4EE402F5-D57F-43D0-96B4-CB07A643D491Q26991693-EE5547A3-1FBE-4ED6-8C40-30123A3625A8Q27004638-DAF1EAFF-4BE5-45DD-A458-0E7B4F46F0F4Q27015533-29508316-D65C-4101-934C-214741F38349Q28083455-AA03EDA3-F06D-4C34-9B36-11E033139216Q30760301-8ACD9053-59EC-49D3-A02A-D4DA2FE976FCQ33686718-E074BE0E-39FD-4B3B-81EF-66F94292FF46Q33739148-F51AD95B-B181-439C-9464-112375FC60D7Q34043846-FC85B3AB-793F-403C-8DF2-8AA65FB7EA4FQ34538249-B79D0740-B451-4515-BD0A-E8B1ACAAC322Q35564107-509B7418-7187-4DF4-A42D-C1DC084D5FE1Q35779257-8B2A2102-E2CB-44DE-AC7E-7E4C7A17AA3AQ36418910-CEE382D9-CC84-4C00-9AB0-D70F5326C5BFQ36429698-0D77E35E-850A-4F82-9C51-507A2D5CAB69Q37330081-953C9FB1-84D5-4542-9C7F-497971E5F5F6Q37498810-C5F4F3C9-8D2C-4F20-90C4-91E11EADD643Q37512884-6DBD05A2-A9D3-4E39-A6D1-C770F9F48EFEQ37686009-D53611C9-611F-4EE1-AFA6-7919EC40066AQ38056967-17D31FA5-7CD9-4AE6-BEDF-969D5E3F944CQ38098466-1943CD06-DBCB-4CA2-87F4-98446E5DB55DQ38110734-848CE48D-16C7-46F0-8A4C-65C389F1A5A1Q38118781-C1C02621-0798-4682-8E83-C0F9B922193BQ38148599-968D4971-0964-4C8A-A4B0-08CB9141DBBFQ38154889-97EB762F-09A2-49BE-9669-7232B115F0D7Q38165235-5BFC88DA-FD93-4462-ABE0-2E2E11AD0EB7Q38211189-0322C524-7B3A-4F5C-BBFC-3B20EA8FFB0FQ38221173-6BA3EAD3-4A5D-4EA1-BC1C-506E2A9A6AB9Q38254127-4E3C91B7-EB0F-4076-8DE0-95348B1EB364Q38295616-245B73B9-7656-42C7-B472-1682F0A991DAQ38434277-0F293D8E-57D2-4520-9B0B-924969F9AEA0Q38445314-1BC57FA3-3159-40CA-9592-61676305A29EQ38458004-CF74A03A-A176-4DA1-9546-C99369D6A16AQ38569875-6436261A-E453-41F6-ABB8-44CED4475517Q38764716-ECB8B78F-D7A7-4348-ABDC-97ACECD3B9BBQ38792080-1025C16C-19CA-4B6B-B688-3CF96564D68DQ38799600-6F43FF6A-2954-42C9-8B34-2056315EF845
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Role of IL-17 in psoriasis and psoriatic arthritis.
@en
Role of IL-17 in psoriasis and psoriatic arthritis.
@nl
type
label
Role of IL-17 in psoriasis and psoriatic arthritis.
@en
Role of IL-17 in psoriasis and psoriatic arthritis.
@nl
prefLabel
Role of IL-17 in psoriasis and psoriatic arthritis.
@en
Role of IL-17 in psoriasis and psoriatic arthritis.
@nl
P2860
P1476
Role of IL-17 in psoriasis and psoriatic arthritis.
@en
P2093
Siba P Raychaudhuri
P2860
P2888
P304
P356
10.1007/S12016-012-8307-1
P577
2013-04-01T00:00:00Z